KR102441221B1 - 농도-의존적 자가-상호작용 나노입자 분광법을 사용하는 단백질의 자가-결합하는 능력을 결정하기 위한 분석 - Google Patents

농도-의존적 자가-상호작용 나노입자 분광법을 사용하는 단백질의 자가-결합하는 능력을 결정하기 위한 분석 Download PDF

Info

Publication number
KR102441221B1
KR102441221B1 KR1020197006376A KR20197006376A KR102441221B1 KR 102441221 B1 KR102441221 B1 KR 102441221B1 KR 1020197006376 A KR1020197006376 A KR 1020197006376A KR 20197006376 A KR20197006376 A KR 20197006376A KR 102441221 B1 KR102441221 B1 KR 102441221B1
Authority
KR
South Korea
Prior art keywords
protein
concentration
absorbance
salt
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020197006376A
Other languages
English (en)
Korean (ko)
Other versions
KR20190039185A (ko
Inventor
마이클 말로우
마이클 세네트
마이클 슈네이더
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Priority to KR1020227030436A priority Critical patent/KR102534506B1/ko
Publication of KR20190039185A publication Critical patent/KR20190039185A/ko
Application granted granted Critical
Publication of KR102441221B1 publication Critical patent/KR102441221B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/314—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N2021/258—Surface plasmon spectroscopy, e.g. micro- or nanoparticles in suspension

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
KR1020197006376A 2016-08-18 2017-08-18 농도-의존적 자가-상호작용 나노입자 분광법을 사용하는 단백질의 자가-결합하는 능력을 결정하기 위한 분석 Expired - Fee Related KR102441221B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227030436A KR102534506B1 (ko) 2016-08-18 2017-08-18 농도-의존적 자가-상호작용 나노입자 분광법을 사용하는 단백질의 자가-결합하는 능력을 결정하기 위한 분석

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376788P 2016-08-18 2016-08-18
US62/376,788 2016-08-18
PCT/US2017/047630 WO2018035470A1 (en) 2016-08-18 2017-08-18 Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227030436A Division KR102534506B1 (ko) 2016-08-18 2017-08-18 농도-의존적 자가-상호작용 나노입자 분광법을 사용하는 단백질의 자가-결합하는 능력을 결정하기 위한 분석

Publications (2)

Publication Number Publication Date
KR20190039185A KR20190039185A (ko) 2019-04-10
KR102441221B1 true KR102441221B1 (ko) 2022-09-07

Family

ID=59746357

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197006376A Expired - Fee Related KR102441221B1 (ko) 2016-08-18 2017-08-18 농도-의존적 자가-상호작용 나노입자 분광법을 사용하는 단백질의 자가-결합하는 능력을 결정하기 위한 분석
KR1020227030436A Active KR102534506B1 (ko) 2016-08-18 2017-08-18 농도-의존적 자가-상호작용 나노입자 분광법을 사용하는 단백질의 자가-결합하는 능력을 결정하기 위한 분석
KR1020237016537A Active KR102717462B1 (ko) 2016-08-18 2017-08-18 농도-의존적 자가-상호작용 나노입자 분광법을 사용하는 단백질의 자가-결합하는 능력을 결정하기 위한 분석

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227030436A Active KR102534506B1 (ko) 2016-08-18 2017-08-18 농도-의존적 자가-상호작용 나노입자 분광법을 사용하는 단백질의 자가-결합하는 능력을 결정하기 위한 분석
KR1020237016537A Active KR102717462B1 (ko) 2016-08-18 2017-08-18 농도-의존적 자가-상호작용 나노입자 분광법을 사용하는 단백질의 자가-결합하는 능력을 결정하기 위한 분석

Country Status (19)

Country Link
US (3) US11428695B2 (cg-RX-API-DMAC7.html)
EP (2) EP3761035B1 (cg-RX-API-DMAC7.html)
JP (3) JP6959327B2 (cg-RX-API-DMAC7.html)
KR (3) KR102441221B1 (cg-RX-API-DMAC7.html)
CN (2) CN115468919A (cg-RX-API-DMAC7.html)
AU (2) AU2017313150B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019003175A2 (cg-RX-API-DMAC7.html)
CA (3) CA3254460A1 (cg-RX-API-DMAC7.html)
DK (2) DK3500856T3 (cg-RX-API-DMAC7.html)
EA (1) EA201990316A1 (cg-RX-API-DMAC7.html)
ES (2) ES2974961T3 (cg-RX-API-DMAC7.html)
FI (1) FI3761035T3 (cg-RX-API-DMAC7.html)
HU (2) HUE052805T2 (cg-RX-API-DMAC7.html)
IL (2) IL264640B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019001930A (cg-RX-API-DMAC7.html)
PL (2) PL3500856T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201900895QA (cg-RX-API-DMAC7.html)
WO (1) WO2018035470A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201901035B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201990316A1 (ru) 2016-08-18 2019-07-31 Ридженерон Фармасьютикалз, Инк. Анализ для определения потенциала самоассоциации белка с использованием концентрационно-зависимой спектроскопии самовзаимодействия на основе наночастиц
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
CN113588582B (zh) * 2020-04-30 2024-05-14 上海药明生物技术有限公司 蛋白质样品浓度测定方式选择法及测定方法
WO2023095154A1 (en) * 2021-11-24 2023-06-01 Sensoville Biotech Pvt Ltd Method for determining changes in a protein's structure
AU2023208644A1 (en) * 2022-01-24 2024-07-04 Amgen Inc. Methods for detecting antibody self-association
CN119832975A (zh) * 2024-12-24 2025-04-15 上海药明生物技术有限公司 一种蛋白质共处方制剂的稳定性预测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160074515A1 (en) * 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2016115475A1 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Anti-cd40 antibody formulations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US771997A (en) 1903-11-21 1904-10-11 Alfred Palm Lathe attachment.
US4254102A (en) * 1975-09-08 1981-03-03 Plough, Inc. Substantive PABA compositions
US4080264A (en) 1976-03-01 1978-03-21 Massachusetts Institute Of Technology Immunoassay by light scattering spectroscopy
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US20050214356A1 (en) * 2004-03-24 2005-09-29 Joyce Timothy H Self assembling activation agents targeted using active drug release
US20050221507A1 (en) * 2004-03-30 2005-10-06 Intel Corporation Method to detect molecular binding by surface-enhanced Raman spectroscopy
US7514938B2 (en) 2004-05-11 2009-04-07 Board Of Regents Of The University And College System Of Nevada, On Behalf Of The University Of Nevada, Reno Dielectric relaxation spectroscopy apparatus and methods of use
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
ES2352509T3 (es) * 2005-05-02 2011-02-21 Baseclick Gmbh Nuevas estrategias de marcaje para la detección sensible de analitos.
US20070291265A1 (en) 2006-04-13 2007-12-20 Mississippi State University Optical apparatus for simultaneously measuring the scattering and concentration of signals of macromolecules in a flow cell
KR20090069330A (ko) * 2006-10-12 2009-06-30 와이어쓰 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
GB0621050D0 (en) * 2006-10-23 2006-11-29 Univ Strathclyde Functionalised polymers for labelling metal surfaces
DK2150617T3 (en) 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
JP2011520769A (ja) * 2007-09-21 2011-07-21 サイトイミューン サイエンシズ インコーポレイテッド ナノ治療コロイド金属組成物および方法
WO2010059963A2 (en) 2008-11-21 2010-05-27 The Board Of Regents Of The University Of Texas System Preparation and methodology of silk fibroin nanoparticles
US20140024024A1 (en) * 2012-07-17 2014-01-23 General Electric Company Methods of detecting dna, rna and protein in biological samples
JP6099108B2 (ja) 2013-05-30 2017-03-29 公立大学法人大阪府立大学 被検出物質の検出装置および方法
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP2902503A1 (en) * 2014-01-31 2015-08-05 Fundación Imdea Nanociencia Functionalized metal nanoparticles and uses thereof for detecting nucleic acids
CN104062287B (zh) * 2014-07-01 2017-08-08 福建工程学院 一种基于纳米金催化的化学发光分析检测铁蛋白的方法
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
EA201990316A1 (ru) 2016-08-18 2019-07-31 Ридженерон Фармасьютикалз, Инк. Анализ для определения потенциала самоассоциации белка с использованием концентрационно-зависимой спектроскопии самовзаимодействия на основе наночастиц

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160074515A1 (en) * 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2016115475A1 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Anti-cd40 antibody formulations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JIEMIN WU et al., ‘Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy’, Protein Engineering, Design & Selection, 2015, Vol.*
PAOLO AROSIO et al., ‘On the role of salt type and concentration on the stability behavior of a monoclonal antibody solution’, Biophysical Chemistry, 2012, Vol. 168-169, pp 19-27. 1부.*
SHANTANU VL SULE et al., ‘High-throughput analysis of concentration-dependent antibody self-association’, Biophysical Journal, 2011, Vol. 101, pp 1749-1757. 1부.*
STEVEN B. GENG et al., ‘Facile preparation of stable antibody-gold conjugates and application to affinity-capture self-interaction nanoparticle spectroscopy’, Bioconjugate Chem., (2016.08.05.), Vol. 2*
STEVEN B. GENG et al., ‘Measurements of monoclonal antibody self-association are correlated with complex biophysical properties’, Mol. Pharmaceutics, 2015, Vol. 13, pp 1636-1645. 1부.*

Also Published As

Publication number Publication date
FI3761035T3 (fi) 2024-03-18
EP3761035B1 (en) 2024-02-14
WO2018035470A9 (en) 2018-07-05
US20240280582A1 (en) 2024-08-22
JP2022008959A (ja) 2022-01-14
MX2023013583A (es) 2023-11-30
KR20190039185A (ko) 2019-04-10
CA3254461A1 (en) 2025-07-03
PL3761035T3 (pl) 2024-06-24
SG11201900895QA (en) 2019-02-27
JP2023139189A (ja) 2023-10-03
ES2837093T3 (es) 2021-06-29
US11988668B2 (en) 2024-05-21
AU2023274236A1 (en) 2023-12-21
MX2019001930A (es) 2019-07-04
CN109661577B (zh) 2022-09-27
IL307435A (en) 2023-12-01
PL3500856T3 (pl) 2021-04-19
EP3500856B1 (en) 2020-10-07
JP7321227B2 (ja) 2023-08-04
US20220357335A1 (en) 2022-11-10
KR20230074614A (ko) 2023-05-30
HUE052805T2 (hu) 2021-05-28
DK3761035T3 (da) 2024-03-11
IL264640B1 (en) 2023-11-01
JP6959327B2 (ja) 2021-11-02
ES2974961T3 (es) 2024-07-02
KR20220126801A (ko) 2022-09-16
KR102534506B1 (ko) 2023-05-30
KR102717462B1 (ko) 2024-10-16
WO2018035470A1 (en) 2018-02-22
EA201990316A1 (ru) 2019-07-31
ZA201901035B (en) 2024-06-26
US20190187149A1 (en) 2019-06-20
JP2019532267A (ja) 2019-11-07
IL264640B2 (en) 2024-03-01
DK3500856T3 (da) 2020-12-14
CA3032361A1 (en) 2018-02-22
US11428695B2 (en) 2022-08-30
CN109661577A (zh) 2019-04-19
CN115468919A (zh) 2022-12-13
AU2017313150B2 (en) 2023-09-14
EP3761035A1 (en) 2021-01-06
IL264640A (cg-RX-API-DMAC7.html) 2019-04-30
BR112019003175A2 (pt) 2019-06-18
AU2017313150A1 (en) 2019-02-21
EP3500856A1 (en) 2019-06-26
CA3254460A1 (en) 2025-07-03
CA3032361C (en) 2025-07-08
HUE066064T2 (hu) 2024-07-28

Similar Documents

Publication Publication Date Title
US11988668B2 (en) Concentration-dependent self-interaction assay
KR101808367B1 (ko) 생물약제학적 약물을 포함하는 약제학적 제제
JP2019034967A (ja) 免疫グロブリン単一可変ドメインの安定製剤及びその使用
JP2021522209A (ja) ヒト抗ｐｄ−ｌ１抗体の配合物
WO2022159349A1 (en) Immunomodulatory antibodies and uses thereof
HK40033565B (en) Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy
HK40033565A (en) Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy
AU2020208397A1 (en) Formulations of antibodies that bind human CD137 and uses thereof
JP2021534393A (ja) 疑似インビボ条件での治療用タンパク質の選択
HK40003495A (en) Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy
HK40003495B (en) Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy
EA043996B1 (ru) Анализ для определения потенциала самоассоциации белка с использованием концентрационно-зависимой спектроскопии самовзаимодействия на основе наночастиц

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250903

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250903

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250903